Top
US_Flag An official website of the United States government Here's how you know
GOV

The .gov means it's official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

LOCK

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

 
U.S. Food & Drug Administration
Continuing Education and Accreditation
Division of Learning and Organizational Development
Center for Drug Evaluation and Research
Activity Outline
CDER Compliance Conference
January 14, 2021
Webcast

Activity Coordinators:
Lisa Misevicz (lisa.misevicz@fda.hhs.gov),  RENEE WILLIAMS (RENEE.WILLIAMS2@FDA.HHS.GOV)
Description

Participants will learn from FDA subject matter experts on a range of drug compliance topics including compounding in cleanrooms, drug importation requirements, drug supply chain security act implementation, and Risk Evaluation and Mitigation Strategies (REMS) compliance.

References
  • Drug Supply Chain Security Act (DSCSA) https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa
  • FDA Risk Evaluation and Mitigation Strategies
  • REMS https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems
Learning Objectives
  • List 5 cleanroom best practices.
  • Explain REMS and how they are created.
  • Describe FDA import requirements.
Target Audience
This activity is intended for physicians, pharmacists, and nurses.
Agenda
Day 1 January 14, 2021
Time Topic Speaker
9:00 - 9:15 AM EST Overview Brenda Stodart, PharmD, MS, BCGP, RAC
9:15 - 9:25 AM EST Keynote DONALD ASHLEY, JD
9:25 - 10:25 AM EST Compounding: Cleanrooms and Cleanroom Behaviors: Why they Matter Djamila Harouaka, PhD
10:25 - 10:45 AM EST Break
10:45 - 11:45 AM EST Enhanced Drug Distribution Security – Drug Supply Chain Security Act (DSCSA) Implementation Updates Connie Jung, PhD, R. Ph
11:45 - 1:00 PM EST Lunch Break Not offered for CE
1:00 - 2:00 PM EST A Glance at Drug Importation Requirements Cristina Dar
2:00 - 2:20 PM EST Break
2:20 - 3:20 PM EST Risk Evaluation and Mitigation Strategies (REMS) Compliance Program Haley Seymour, MS
Continuing Education Accreditation
Jointly Accredited Provider
In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ICPE Credit
This activity was planned by and for the healthcare team, and learners will receive 4.25 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-21-030-L04-P for 4.25 contact hour(s).
CNE
FDA Center for Drug Evaluation and Research designates this activity for 4.25 contact hour(s).
Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Attention Pharmacists and Pharmacy Techs: Failure to provide your correct NABP AND Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721) Do not provide your pharmacy license number. Please click the "My Account" tab and then navigate to "Edit Contact Information" to verify that your information is correct.

Important Note regarding completion of evaluations and receiving credit
Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit.Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 8 weeks after the last session of the activity to obtain their CE credit.
Disclosure

Faculty
  • ASHLEY, DONALD, JD, Director Office of Compliance, FDA - nothing to disclose
  • Dar, Cristina, Senior Science Health Advisor, HHS-FDA-CDRH-OCD - nothing to disclose
  • Harouaka, Djamila, PhD, Senior Scientific Advisor, CDER/OPQ/OQS - nothing to disclose
  • Jung, Connie, PhD, R. Ph, Senior Advisor for Policy, FDA/CDER/Office of Compliance - nothing to disclose
  • Seymour, Haley, MS, Consumer Safety Officer, Food and Drug Administration - nothing to disclose
  • Stodart, Brenda, PharmD, MS, BCGP, RAC, Program Director, FDA - nothing to disclose

Planning Committee
  • Kleppinger, Cynthia, MD, Medical Officer, FDA - nothing to disclose
  • Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/DDI - nothing to disclose
  • Stodart, Brenda, PharmD, MS, BCGP, RAC, Program Director, FDA - nothing to disclose

CE Consultation and Accreditation Team
  • Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
  • Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose
Registration Information
Registration is complimentary; therefore refunds are not applicable.
Requirements for Certificate of Completion (Non CE)
Must attend 90% of the activity.